Gary RieschelCo-Founder and Partner
Gary Rieschel has over 35 years of successful operating and investing experience as a senior executive, entrepreneur, investor, and global business strategist. Gary has held executive positions at Intel, Sequent Computer, Cisco Systems, and Softbank Corporation. Over the last 20 years as a venture capitalist, he led investments in 13 companies in the US and China which grew to over $1B USD in market capitalization. Gary aided in the creation of the venture capital industry in China through sponsoring and founding several of China’s leading VC firms including Softbank China Ventures, SAIF Partners (2001), Ceyuan Ventures (2004), and Qiming Venture Partners (2006). He is Founding Managing Partner of Qiming, one of China’s preeminent VC firms with over $4.3B under management. In 2016, Gary returned to the States after 12 years in China to launch Qiming’s first operation in the US. Qiming US has over $300M USD under management invested in cutting edge healthcare investments. Gary serves on the board of Nuvaira and remains on Qiming’s Executive and Investment Committees. He also serves on the board of Lanzatech, a leading environmental biotech company.
Gary is well regarded as a mentor to entrepreneurs, founders, and other venture capitalists. He is on the board of many preeminent environmental organizations including The Nature Conservancy (Montana), PERC (Free Market Environmentalism), the Climate Leadership Council, the Asia Society (Advisor), and helped introduce the Rocky Mountain Institute into China. Gary also serves on the board of the US Olympic Foundation and is a permanent member of the Council on Foreign Relations.
Gary holds a BA in Biology from Reed College in Portland, OR where he is a long time Trustee, and an MBA from the Harvard Business School. He lived in Japan for five years in the late 1980s and in Shanghai from 2005 through 2016. He now resides in Seattle, WA.
Mark BonyhadiSenior Advisor
Mark Bonyhadi, PhD is a Senior Advisor at Qiming Venture Partners USA, based in Seattle, WA. Prior to joining Qiming USA in December of 2018, Mark held positions of Vice President of Research, Head of Academic Affairs, and Vice President of Process Research Sciences from 2013-2018 at Juno Therapeutics (acquired by Celgene Corporation).
From 2006-2013, Mark was Director of Global Business Development for Cell Therapy at Invitrogen, which was merged with Applied BioSystems, to create Life Technologies, which subsequently was acquired by Thermo-Fisher. Mark was responsible for identifying and implementing business opportunities aligned with the Lifetech/Invitrogen/Thermo cellular medicine portfolio, participating and leading in the launch of the Cell Therapy Systems (CTS™) product line optimized for cell therapy applications, as well as working with academia and industry to accelerate the development of novel cell and/or gene-based therapies.
From 1997-2005, Mark served as Director and later Vice President of Research at Xycte Therapies, a public Seattle-based T cell therapy company treating cancer, infectious disease and autoimmunity. Before heading to Xcyte, Mark spent from 1990-1997 working his way up to a Senior Scientist level at SyStemix, a public Palo Alto-based biotech company developing hematopoietic stem cell based therapies for treating cancer, as well as gene-therapy approaches for treating HIV infection. The latter was a collaborative effort with Sandoz, which later merged with Ciba Geigy to become Novartis.
Mark did his Postdoctoral training at SyStemix with Dr. Mike McCune and Dr. Hideto Kaneshima studying HIV pathogenesis in the SCID-hu mouse model. Mark is a former Chair and current member of the Industry Liaison Committee for the American Society for Gene and Cell Therapy (ASGCT).
Mark received a B.A. from Reed College, Portland, OR and a PhD from UC Berkeley in the lab of James P. Allison, where he studied T cell immunology. Since graduating from UC Berkeley, Mark has been focused on the development of commercially viable approaches for bringing cell therapies, gene-modified cell therapies, and regenerative medicine from the bench, to the clinic, and into commercial use over the past three decades.
Mark currently lives in Seattle, WA.
Mark McDadeCo-Founder and Partner
Mark McDade joined Qiming Venture Partners USA in 2017 and is based in Cambridge, MA. Before joining the Qiming team, Mark was Executive Vice President, COO at UCB. He led UCB’s worldwide Geographic Operations, Established Brands, Technical Operations and Business Development. He joined UCB’s Executive Committee in 2008.
From 2002 until late 2007, Mark served as CEO and Director of PDL Biopharma, an antibody-based biopharma company located in Redwood City, CA. Prior to PDL, he served as CEO of Signature Bioscience, located in San Francisco, CA. Mark was founder and a director of Corixa Corporation, where he served as COO from September 1994 to December 1998 and as President and COO from January 1999 until his departure in late 2000 to join Signature. Before Corixa, Mark was COO of Boehringer Mannheim Therapeutics, the biopharmaceutical division of Corang. Prior to that he held several positions at Sandoz Ltd. including business development, product management and general management.
Mark previously served on the boards of Aimmune Therapeutics (acquired by Nestlé) and Dermira (acquired by Eli Lilly & Company). Mark received a BA from Dartmouth College and an MBA from the Harvard Business School.
Mark serves on the boards of Cadent Therapeutics, LetsGetChecked, myHealthteams, PlateletBio, Talaris Therapeutics, and WindMIL Therapeutics. He led investments in Kezar Life Sciences (NASDAQ: KZR) and Twine Health (acquired by FitBit).
Anna French, DPhil joined Qiming Venture Partners USA in 2017 and is based in Cambridge, MA. Prior to joining the Qiming team, Anna was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and operations. She also led a global industry-academic consortium focused on cell therapy commercialization.
Anna earned a D.Phil from the University of Oxford, UK where her research focused on hematological differentiation of human induced pluripotent stem (iPS) cells. She has over 20 publications in the field of stem cell research.
Anna currently serves on the boards of WindMIL Therapeutics, Jasper Therapeutics, Umoja Biopharma, Auron Therapeutics and Cardialen. She is a board observer with Talaris Therapeutics and PlateletBio.
Colin Walsh, Ph.D. joined Qiming Venture Partners USA in April 2019 and is based in South San Francisco, CA. He currently serves on the boards of Elevation Oncology, Korro Bio and Element Science and is a board observer of Amphivena Therapeutics and Icosavax.
Before joining Qiming in 2019, Colin was a Vice President on the life science investment team at ND Capital where he sourced, structured, and managed investments in biotech, biopharma, and platform companies. Prior to NanoDimension, he held a number of roles as an early employee at Precision NanoSystems, a 5AM Ventures backed biotech developing a suite of technologies to enable the development of RNA-based therapeutics and other complex drug formulations.
Colin earned a Ph.D. from the UC Berkeley – UCSF Graduate Program in Bioengineering where he worked on novel delivery systems for RNA therapeutics as an NSF Graduate Research Fellow. He holds a Management of Technology certificate from the UC Berkeley Haas School of Business, and a dual BS with Honors in Chemical Engineering and Biochemistry from the University of Massachusetts, Amherst.
Colin currently serves on the business advisory board for the Harvard Medical School Initiative for RNA Medicine. He is also an advisor to the Stanford SPARK program and the UCSF Catalyst program where he provides mentorship and support to student- and faculty-led translational research projects.
Franklin BergerSenior Advisor
Franklin currently serves on the board of six public biotechnology companies: Five Prime Therapeutics (NASDAQ: FPRX), Bellus Health (NASDAQ: BLU), ESSA Pharma (NASDAQ: EPIX), Proteostasis (NASDAQ:PTI), Tocagen (NASDAQ: TOCA), and Kezar Life Sciences (NASDAQ:KZR). Previous public company board service includes eleven years with Seattle Genetics, seven years with VaxGen, (vaccines/biodefense) and Aurinia (previously Isotechnika), based in Canada. He also serves or has served on private biotech company boards including Atreca, Applied Therapeutics, Immune Design, (acquired by Merck in 2019), Rain Therapeutics, CERUS Endovascular, Caprion Proteomics, (sold in July 2012) and ViroChem Pharma, which was purchased by Vertex Pharmaceuticals, for $400 million in 2009. Franklin has led multiple M&A analyses resulting in >$3 billion in transaction value.
Franklin started his consulting practice in 2003 after leaving J. P. Morgan Securities, Inc. as head of biotechnology equity research. His clients were exclusively biotechnology industry participants including major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital companies. Assignments included business development, strategic advisory/financings, partnering and royalty acquisitions. Some of his past mandates include Stemcentrx, PDL BioPharma, Inc., Intra-Cellular Therapeutics, Serono, Merck KGaA, Threshold Pharmaceuticals, Valeant (formerly Biovail), Kleiner Perkins Caufield & Byers.
As a senior portfolio manager on the buy-side, Franklin worked at Sectoral Asset Management as a co-founder of the small-cap focused NEMO Fund from 2007 through June 2008. He reduced his consulting practice commitment during his full time employment with Sectoral Asset Management.
Franklin spent twelve years in sell-side equity research, most recently as Managing Director, U.S. Equity Research, J. P. Morgan Securities, Inc., from May 1998 to March 2003. During his five years at J. P. Morgan Securities, Inc., he was involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities. Most of these transactions were lead-managed and book-run by the J. P. Morgan Biotech Team. He was associated with several notable financings in the biotechnology sector including the Genentech IPO, then the largest biotechnology IPO financing ever executed, the first large Celgene Corporation financings as well as several large-cap biotechnology companies in their rapid growth phase. His team covered 26 publicly-traded biotechnology companies. Franklin began his career as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research and Senior Biotechnology Analyst.
Institutional Investor Magazine ranked Franklin #3 on J. P. Morgan’s All-Star Research Team. The Wall Street Journal selected him as the No. 1 ranked biotechnology analyst in its All-Star Analyst Survey in 1997 and No. 2 ranked in the WSJ’s 2000 Survey. In 2000, he became a Founding Fellow of the Biotechnology Study Center at New York University School of Medicine.
Franklin received his MBA from Harvard Business School in 1975; Johns Hopkins University conferred both his MA and AB degrees in 1971 and 1972, respectively.
Robert HeadleySenior Advisor
Robert Headley is a partner at Ignition. He joined the firm in 2000. Robert has led fundraising efforts for more than $2 billion in capital commitments across seven Ignition and affiliated funds.
Robert previously served as a director for Enclarity (acquired by LexisNexis), Extend America (acquired by Spring) and several other Ignition portfolio companies.
Prior to joining Ignition, Robert spent seven years at Starbucks Coffee Company, most recently as vice president, finance & treasurer. In that role, he managed Starbucks investor relations, corporate development, Treasury, business planning & analysis, and profit improvement functions.
Before Starbucks, Robert spent three years in the principal investment area and investment banking division of Goldman Sachs in New York and Sydney, Australia.
Robert holds an MS and BS degree with distinction in industrial engineering from Stanford University.
Will McConnell joined the Qiming team in early 2020 and is based in the Cambridge, MA office. Prior to joining the firm he worked at Biomatics Capital, an early stage life sciences-focused venture fund, as an investment analyst with responsibilities in pipeline evaluation, diligence activities, and portfolio support. Prior to Biomatics Will worked in strategy consulting at L.E.K. Consulting, where he primarily focused on business development strategy and transactional support for a range of healthcare clients (discovery / clinical-stage biotechs to large biopharmas).
Will holds a B.A. from Dartmouth College in Biology and Computer Science, where he was also a member of the Division I basketball team. In his free time the San Francisco-Bay Area native enjoys traveling and playing pick-up basketball, though with increasingly declining aptitude.
Phil DiGiacomo joined the Qiming Venture Partners USA team in July 2020 as an Associate based in the South San Francisco, CA office.
Prior to joining Qiming, Phil spent several years as a part-time associate at ND Capital while completing his PhD. He focused on the sourcing and diligence of early-stage life science companies, as well as portfolio support.
Phil completed his PhD in Bioengineering at Stanford University where his research focused on the discovery and development of novel biomarkers and therapeutic targets for neuroinflammatory diseases as a SPARK Translational Research Fellow and Training in Imaging and Instrumentation Fellow. He holds a Master’s of Science in Medicine from the Stanford University School of Medicine and a Bachelor’s with Distinction in Mathematics, Cognitive Science, and Biomedical Engineering from the University of Virginia.